TC BioPharm (Holdings) (TC BioPharm (Holdings)) Land And Improvements : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Land And Improvements?

TC BioPharm (Holdings)'s land and improvements for the quarter that ended in Mar. 2024 was $0.00 Mil.

TC BioPharm (Holdings) Land And Improvements Historical Data

The historical data trend for TC BioPharm (Holdings)'s Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Land And Improvements Chart

TC BioPharm (Holdings) Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

TC BioPharm (Holdings) Quarterly Data
	Dec19	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
Land And Improvements	Get a 7-Day Free Trial							-	-	-	-	-

TC BioPharm (Holdings) Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

T0U:Germany

Address

Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR

Website

https://www.tcbiopharm.com

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.

Executives

Renaissance Capital Partners Ltd	10 percent owner	42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD